Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 8/20 | 0.49 |
| ▸ | PPARG | P37231 | 3/20 | 0.49 |
| ▸ | MMP8 | P22894 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.40 |
| ▸ | NPY1R | P25929 | 1/20 | 0.40 |
| ▸ | NPY2R | P49146 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | CPA1 | P15085 | 1/20 | 0.40 |
| ▸ | CPA3 | P15088 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4734008 | 0.85 | CYP1A2 (0.58) | EPHX2CYP1A2CPA1CPA3 | |
| SCHEMBL563663 | 0.82 | PPARG (0.53) | EPHX2PPARGMMP8MEN1NPC1 | |
| SCHEMBL10521821 | 0.82 | MMP8 (0.61) | EPHX2PPARGMMP8MEN1NPC1 | |
| SCHEMBL14207099 | 0.79 | EPHX2 (0.40) | EPHX2PPARGMMP8MEN1NPC1 | |
| SCHEMBL15479082 | 0.79 | PPARG (0.58) | EPHX2PPARGMMP8MEN1NPC1 | |
| SCHEMBL3504311 | 0.79 | EPHX2 (0.70) | EPHX2PPARGMMP8MEN1NPC1 | |
| SCHEMBL444331 | 0.79 | ADORA3 (0.47) | EPHX2PPARGMEN1NPC1KMT2A | |
| SCHEMBL3696782 | 0.79 | ADORA3 (0.47) | EPHX2PPARGMEN1NPC1KMT2A | |
| SCHEMBL3205323 | 0.79 | ADORA3 (0.47) | EPHX2PPARGMEN1NPC1KMT2A | |
| SCHEMBL442023 | 0.79 | ADORA3 (0.47) | EPHX2PPARGMEN1NPC1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1888727-B1 | NEW DHA DERIVATIVES AND THEIR USE AS MEDICAMENTS | PRONOVA BIOPHARMA NORGE AS (NO) | 2015-04-15 | — | — | EP | disclosed |
| US-20120065260-A1 | NOVEL COMPOUNDS | Pronova BioPhrma Norge AS | 2012-03-15 | — | — | US | disclosed |
| US-20120065260-A1 | NOVEL COMPOUNDS | Pronova BioPhrma Norge AS | 2012-03-15 | — | — | US | disclosed |
| US-8034842-B2 | Compounds | PRONOVA BIOPHARMA NORGE AS (NO) | 2011-10-11 | — | — | US | disclosed |
| US-8034842-B2 | Compounds | PRONOVA BIOPHARMA NORGE AS (NO) | 2011-10-11 | — | — | US | disclosed |
| US-7550613-B2 | alpha-methoxy docosahexanoic acid ethyl ester, alpha-iodo-docosahexanoic acid ethyl ester; antidiabetic for diabetes type 2, cardiovascular disorders, obesity, amyloidosis, prophylaxis; free of 4,7,10,13,16,19-docosahexanoic acid ( DHA), alpha-methyl DHA, alpha-methyl DHA-methyl ester | PRONOVA BIOPHARMA NORGE AS (NO) | 2009-06-23 | — | — | US | disclosed |
| US-7550613-B2 | alpha-methoxy docosahexanoic acid ethyl ester, alpha-iodo-docosahexanoic acid ethyl ester; antidiabetic for diabetes type 2, cardiovascular disorders, obesity, amyloidosis, prophylaxis; free of 4,7,10,13,16,19-docosahexanoic acid ( DHA), alpha-methyl DHA, alpha-methyl DHA-methyl ester | PRONOVA BIOPHARMA NORGE AS (NO) | 2009-06-23 | — | — | US | disclosed |
| US-20080300306-A1 | Novel Compounds | BRYHN MORTEN | 2008-12-04 | — | — | US | disclosed |
| US-20080300306-A1 | Novel Compounds | BRYHN MORTEN | 2008-12-04 | — | — | US | disclosed |
| US-20070088170-A1 | Novel compounds | PRONOVA BIOPHARMA NORGE AS (NO) | 2007-04-19 | — | — | US | disclosed |
| US-20070088170-A1 | Novel compounds | PRONOVA BIOPHARMA NORGE AS (NO) | 2007-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070088170-A1 | Novel compounds | FFAR2, GPR119, ALOX12 | EPHX2 281/4885PPARG 104/4885MMP8 3230/4885 |
| US-20080300306-A1 | Novel Compounds | GPR119, FFAR2, ALOX12 | EPHX2 287/4885PPARG 118/4885MMP8 3125/4885 |
| US-20120065260-A1 | NOVEL COMPOUNDS | FFAR2, GPR119, ALOX12 | EPHX2 281/4885PPARG 104/4885MMP8 3230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.